Q1 2026 Earnings Call

GLP-1 Momentum Under Scrutiny

Eli Lilly enters 2026 riding high after reporting blockbuster 2025 results, with revenue surging 45% to around $65 billion, largely fueled by its incretin portfolio. Mounjaro (for diabetes) and Zepbound (for obesity) together generated tens of billions in sales, propelling the company to become the world's most valuable drugmaker at points during the year.

In early February 2026, Lilly issued aggressive full-year guidance of $80 billion to $83 billion in revenue—a 25% midpoint increase—and non-GAAP EPS of $33.50 to $35.00, both well above analyst expectations. This optimism contrasts sharply with Novo Nordisk's outlook for potential 2026 sales declines of 5-13%, hit by U.S. pricing concessions and expiring exclusivities in markets like China.

The April 30 earnings call arrives roughly a quarter into the year, providing the first concrete data on whether Lilly is tracking toward its targets. Demand for GLP-1 therapies remains robust, but challenges loom: manufacturing scale-up efforts continue, potential competition from emerging oral options intensifies, and broader pricing dynamics—including recent Medicare negotiations—could compress margins.

Non-obvious tensions include the trade-off between volume growth and profitability; Lilly's high-margin incretins dominate revenue, but expanding access through partnerships or discounts risks eroding per-unit economics. Pipeline readouts for next-generation candidates like orforglipron (oral) add upside, yet any delays could shift focus back to injectable incumbents facing supply bottlenecks in prior years.

Market implications extend beyond shareholders: sustained growth would accelerate Lilly's manufacturing investments, potentially easing global shortages of weight-loss treatments, while any stumble might temper enthusiasm in the obesity sector and affect patient access amid affordability debates.